EDX Medical was founded by Professor Sir Chris Evans OBE, widely regarded as Europe’s most successful and prolific life sciences entrepreneur. Sir Chris brought together longstanding colleagues and experts in the sector including Dr Mike Hudson, CEO, Senior Independent Director Professor Trevor Jones and former UK Government adviser, Jason Holt, to form the core team for the launch of the company.
The Covid-19 pandemic heralded great changes in the diagnostics sector. Demand from health professionals and patients for better, faster diagnosis and treatment highlighted fast-growing need for rapid, reliable and cost-effective testing solutions. New regulations across Europe for in vitro diagnostic medical devices also signalled a new era for diagnostic provision.
EDX Medical is committed to developing and deploying digitally-enabled diagnostic products and services to identify disease risk, improve clinical decision-making and accelerate the development of new medicines in the areas of cancer, heart disease and infectious diseases.
EDX Medical is listed on the Aquis Stock Exchange in London and since its formation has acquired two companies, Hutano Diagnostics Ltd, and Torax Biosciences Ltd to broaden our capabilities.
By translating clinical insights into pragmatic solutions, EDX Medical seeks to enable better outcomes for patients through the personalised management of disease.
